Tissue plasminogen activator use: Evaluation and initial management of ischemic stroke from an Iowa Hospital perspective

Journal of Stroke and Cerebrovascular Diseases

Volumn 14, Issue 3, 2005, Pages 127-135

  Albright, Karen C ^a   Schott, Todd C ^a,b   Jafari, Neda ^a,c   Wohlford Wessels, Mary Pat ^a   Finnerty, Edward P ^a   Jacoby, Michael R K ^d  

^a DES MOINES UNIVERSITY   (United States)

^b UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY   (United States)

^c ARROWHEAD REGIONAL MEDICAL CENTER   (United States)

^d Mercy Ruan Neurology Clinic   (United States)

Author keywords

Guideline adherence; Hospital emergency service; Stroke; Thrombolysis; Tissue plasminogen activator

Indexed keywords

ALTEPLASE;

AGED; ARTICLE; CEREBROVASCULAR ACCIDENT; COMMUNITY HOSPITAL; CONTROLLED STUDY; DRUG SCREENING; DRUG USE; EMERGENCY WARD; FEMALE; FIBRINOLYTIC THERAPY; HEALTH CARE ORGANIZATION; HUMAN; HYPERTENSION; IATROGENIC DISEASE; MAJOR CLINICAL STUDY; MALE; MEDICAL ASSESSMENT; MEDICAL RECORD; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TIME; UNITED STATES;

EID: 18344368632     PISSN: 10523057     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jstrokecerebrovasdis.2005.01.004     Document Type: Article

References (62)

1. American Heart Association. Disease and stroke statistics-2004 update. Available from: UR: http://www.americanheart.org/presenter.jhtml?identifier= 1200026. Accessed August 4, 2004.
2. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group Tissue plasminogen activator for acute ischemic stroke N Engl J Med 333 1995 1581 1587
3. T.G. Kwiatkowski, R.B. Libman, M. Frankel Effects of tissue plasminogen activator for acute ischemic stroke at one year N Engl J Med 340 1999 1781 1787
4. W. Hacke, E. Bluhmki, T. Steiner Dichotomized efficacy end points and global end-point analysis applied to the ECASS intention-to-treat data set Post hoc analysis of ECASS I Stroke 29 1998 2073 2075
5. J.R. Marler, L.B. Goldstein Medicine Stroke-tPA and the clinic Science 301 2003 1677
6. D.M. Bravata, N. Kim, J. Concato Thrombolysis for acute stroke in routine clinical practice Arch Intern Med 162 2002 1994 2001
7. L.B. Morgenstern, L. Staub, W. Chan Improving delivery of acute stroke therapy The TLL Temple Foundation stroke project Stroke 33 2002 160 166
8. D. Chiu, D. Krieger, C. Villar-Cordova Intravenous tissue plasminogen activator for acute ischemic stroke Feasibility, safety, and efficacy in the first year of clinical practice Stroke 29 1998 18 22
9. R.M. Zweifler, M.L. Brody, G.C. Graves Intravenous t-PA for acute ischemic stroke Therapeutic yield of a stroke code system Neurology 50 1998 501 503
10. M. Grond, C. Stenzel, S. Schmulling Early intravenous thrombolysis for acute ischemic stroke in a community-based approach Stroke 29 1998 1544 1549
11. I.L. Katzan, A.J. Furlan, L.E. Lloyd Use of tissue-type plasminogen activator for acute ischemic stroke The Cleveland area experience JAMA 283 2000 1151 1158
12. D.Z. Wang, J.A. Rose, D.S. Honings Treating acute stroke patients with intravenous tPA The OSF stroke network experience Stroke 31 2000 77 81
13. P.A. Barber, J. Zhang, A.M. Demchuk Why are stroke patients excluded from TPA therapy? An analysis of patient eligibility Neurology 56 2001 1015 1020
14. S.C. Johnston, L.H. Fung, L.A. Gillum Utilization of intravenous tissue-type plasminogen activator for ischemic stroke at academic medical centers The influence of ethnicity Stroke 32 2001 1061 1068
15. S.D. Reed, S.C. Cramer, D.K. Blough Treatment with tissue plasminogen activator and inpatient mortality rates for patients with ischemic stroke treated in community hospitals Stroke 32 2001 1832 1840
16. P.U. Heuschmann, K. Berger, B. Misselwitz Frequency of thrombolytic therapy in patients with acute ischemic stroke and the risk of in-hospital mortality The German stroke registers study group Stroke 34 2003 1106 1113
17. I.L. Katzan, M.D. Hammer, E.D. Hixson Utilization of intravenous tissue plasminogen activator for acute ischemic stroke Arch Neurol 61 2004 346 350
18. B.C. Tilley, P.D. Lyden, T.G. Brott Total quality improvement method for reduction of delays between emergency department admission and treatment of acute ischemic stroke The National Institute of Neurological Disorders and Stroke rt-PA stroke study group Arch Neurol 54 1997 1466 1474
19. A. Bhardwaj Assessment of regional acute stroke care Stroke 33 2002 1339 1340
20. E. Feldmann, N. Gordon, J.M. Brooks Factors associated with early presentation of acute stroke Stroke 24 1993 1805 1810
21. A.M. Pancioli, J. Broderick, R. Kothari Public perception of stroke warning signs and knowledge of potential risk factors JAMA 279 1998 1288 1292
22. W.D. Rosamond, R.A. Gorton, A.R. Hinn Rapid response to stroke symptoms The delay in accessing stroke healthcare (DASH) study Acad Emerg Med 5 1998 45 51
23. M.A. Smith, K.M. Doliszny, E. Shahar Delayed hospital arrival for acute stroke The Minnesota stroke survey Ann Intern Med 129 1998 190 196
24. R. Kothari, E. Jauch, J. Broderick Acute stroke Delays to presentation and emergency department evaluation Ann Emerg Med 33 1999 3 8
25. R.E. O'Connor, P. McGraw, L. Edelsohn Thrombolytic therapy for acute ischemic stroke Why the majority of patients remain ineligible for treatment Ann Emerg Med 33 1999 9 14
26. C. Villar-Cordova, L.B. Morgenstern, J.S. Barnholtz Neurologists' attitudes regarding rt-PA for acute ischemic stroke Neurology 50 1998 1491 1494
27. J.F. Meschia, L.S. Williams, J.D. Fleck Views on the use of tissue plasminogen activator in acute ischemic stroke A state-wide survey among neurologists and emergency medicine physicians in Indiana J Stroke Cerebrovasc Dis 8 1999 207 210
28. P.T. Akins, C. Delemos, D. Wentworth Can emergency department physicians safely and effectively initiate thrombolysis for acute ischemic stroke? Neurology 55 2000 1801 1805
29. I.L. Katzan, C.A. Sila, A.J. Furlan Community use of intravenous tissue plasminogen activator for acute stroke Results of the brain matters stroke management survey Stroke 32 2001 861 865
30. L.B. Goldstein, L.A. Hey, R. Laney North Carolina stroke prevention and treatment facilities survey Statewide availability of programs and services Stroke 31 2000 66 70
31. S. Ruland, P.B. Gorelick, M. Schneck Acute stroke care in Illinois A statewide assessment of diagnostic and treatment capabilities Stroke 33 2002 1334 1339
32. M.J. Jacoby, K.C. Albright, T.C. Schott Tissue plasminogen activator utilization in rural Iowa J Stroke Cerebrovasc Dis 12 2003 246
33. H.P. Adams Jr, T.G. Brott, A.J. Furlan Guidelines for thrombolytic therapy for acute stroke A supplement to the guidelines for the management of patients with acute ischemic stroke; a statement for healthcare professionals from a special writing group of the stroke council, American Heart Association Stroke 27 1996 1711 1718
34. R.J. Riopelle, D.C. Howse, C. Bolton Regional access to acute ischemic stroke intervention Stroke 32 2001 652 655
35. J.P. Mohr Thrombolytic therapy for ischemic stroke From clinical trials to clinical practice JAMA 283 2000 1189 1191
36. G. Hademenos Metro stroke task force First-year experience Stroke 30 1999 2512
37. D.Z. Wang It is time to implement stroke practice improvement programs and prevent the racial disparity in stroke care Stroke 32 2001 1067 1068
38. D.Z. Wang IV tPA, much underutilized, does not increase stroke mortality Stroke 32 2001 1840
39. N. Nighoghossian tPA in daily clinical practice Stroke 34 2003 1112 1113
40. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group A systems approach to immediate evaluation and management of hyperacute stroke Experience at eight centers and implications for community practice and patient care Stroke 28 1997 1530 1540
41. W. Hacke, M. Kaste, C. Fieschi Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke The European cooperative acute stroke study (ECASS) JAMA 274 1995 1017 1025
42. W. Hacke, M. Kaste, C. Fieschi Randomized double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischemic stroke (ECASS II) Second European-Australasian acute stroke study investigators Lancet 352 1998 1245 1251
43. The Multicenter Acute Stroke Trial-Europe Study Group Thrombolytic therapy with streptokinase in acute ischemic stroke N Engl J Med 335 1996 145 150
44. G.A. Donnan, S.M. Davis, B.R. Chambers Streptokinase for acute ischemic stroke with relationship to time of administration Australian streptokinase (ASK) trial study group JAMA 276 1996 961 966
45. Multicentre Acute Stroke Trial-Italy (MAST-I) Group Randomized controlled trial of streptokinase, aspirin, and combination of both in treatment of acute ischemic stroke Lancet 346 1995 1509 1514
46. W.M. Clark, S. Wissman, G.W. Albers Recombinant tissue-type plasminogen activator (alteplase) for ischemic stroke 3 to 5 hours after symptom onset The ATLANTIS study; a randomized controlled trial, alteplase thrombolysis for acute noninterventional therapy in ischemic stroke JAMA 282 1999 2019 2026
47. G.W. Albers, W.M. Clark, K.P. Madden ATLANTIS trial Results for patients treated within 3 hours of stroke onset; alteplase thrombolysis for acute noninterventional therapy in ischemic stroke Stroke 33 2002 493 495
48. J.R. Marler, P.W. Jones, M. Emr Setting new directions for stroke care Proceedings of a national symposium on rapid identification and treatment of acute stroke. Publication No. 97-4239 1997 The National Institute of Neurological Disorders and Stroke National Institutes of Health Bethesda (MD)
49. M.J. Alberts, G. Hademenos, R.E. Latchaw Recommendations for the establishment of primary stroke centers Brain attack coalition JAMA 283 2000 3102 3109
50. I.L. Katzan, T.M. Graber, A.J. Furlan Cuyahoga County operation stroke speed of emergency department evaluation and compliance with National Institutes of Neurological Disorders and Stroke time targets Stroke 34 2003 994 998
51. A.M. Buchan, P.A. Barber, N. Newcommon Effectiveness of t-PA in acute ischemic stroke Outcome relates to appropriateness Neurology 54 2000 679 684
52. K.M. Chapman, A.R. Woolfenden, D. Graeb Intravenous tissue plasminogen activator for acute ischemic stroke A Canadian hospital's experience Stroke 31 2000 2920 2924
53. D.L. Morris, W. Rosamond, K. Madden Prehospital and emergency department delays after acute stroke The Genentech stroke presentation survey Stroke 31 2000 2585 2590
54. J.C. Grotta, W.S. Burgin, A. El-Mitwalli Intravenous tissue-type plasminogen activator therapy for ischemic stroke Houston experience 1996 to 2000 Arch Neurol 58 2001 2009 2013
55. A.M. Lopez-Yunez, A. Bruno, L.S. Williams Protocol violations in community-based rTPA stroke treatment are associated with symptomatic intracerebral hemorrhage Stroke 32 2001 12 16
56. J.G. Merino, B. Silver, E. Wong Extending tissue plasminogen activator use to community and rural stroke patients Stroke 33 2002 141 146
57. S.L. Silliman, B. Quinn, V. Huggett Use of a field-to-stroke center helicopter transport program to extend thrombolytic therapy to rural residents Stroke 34 2003 729 733
58. D.L. Morris, W.D. Rosamond, A.R. Hinn Time delays in accessing stroke care in the emergency department Acad Emerg Med 6 1999 218 223
59. L.S. Williams, A. Bruno, D. Rouch Stroke patients' knowledge of stroke Influence on time to presentation Stroke 28 1997 912 915
60. L. Derex, P. Adeleine, N. Nighoghossian Factors influencing early admission in a French stroke unit Stroke 33 2002 153 159
61. W.G. Barsan, T.G. Brott, J.P. Broderick Urgent therapy for acute stroke Effects of a stroke trial on untreated patients Stroke 25 1994 2132 2137
62. S.C. Menon, D.K. Pandey, L.B. Morgenstern Critical factors determining access to acute stroke care Neurology 51 1998 427 432